J&J Gives Up On Botox Rival

Johnson & Johnson announced last week that it will abandon efforts to bring to market a rival drug to Allergan's popular anti-wrinkle treatment, Botox.

Instead, J&J will focus on its core breast surgery business, aided by its 2009 purchase of Mentor, a leading maker of breast implants for cosmetic and reconstructive surgery. This aquisition also gave J&J PurTox, the Botox rival that the company is halting.

J&J also mentioned that ending the PurTox development program will result in a small amount of U.S. layoffs.

Read the Reuters release

More News:

All news »

What are your comments?

You cannot post comments until you have logged in. Login Here.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments